medigraphic.com

2017, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2017; 55 (2)

Use of recombinant Human Growth Hormone (rHGH)

Calzada-León R

Language: Spanish
References: 340
Page: 196-213
PDF size: 363.55 Kb.


ABSTRACT

Recombinant human growth hormone, synthesized in E.coli or mammalian cells cultures, is since 1985, a useful therapeutic resource to increase growth velocity and final height.
In this paper are discussed the four phases (aims, security and efficacy, utility and efficiency) indispensables to define the start of treatment, as well as the absolute, relative and metabolic indications and the transitory and permanent conditions that contraindicate its use.
It is commented the way to optimize the results (simple but indispensables indications for the physician, the patients and their family). Finally it is analyzed the results of treatment in patients with growth hormone deficiency, Turner syndrome, chronic renal failure, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, intrauterine growth retardation and idiopathic short stature.


REFERENCES

  1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18:901-903.

  2. Rimoin DL, Merimee TJ, McKusick VA. Sexual ateliotic dwarfism: A recessively inherited isolated deficiency of growth hormone. Trans Assoc Am Phys. 1966;79:297-311.

  3. McKusick VA, Rimoin DL. General Tom Thumb and other midgets. Sci Am. 1967;217:102-106.

  4. Frasier SD. The not-so-good old days: Working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr. 1997;131:S1-S4.

  5. Cronin MJ. Pioneering recombinant growth hormone manufacturing: Pounds produced per mile of height. J Pediatr. 1997;131:S5-S7.

  6. Lindholm J. Growth hormone: historical notes. Pituitary. 2006;9:5-10.

  7. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160:263-269.

  8. Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev. 2010;18:92-108.

  9. Gupta V. Adult growth hormone deficiency. Indian J Endocrinol Metab. 2011;15(Suppl 3):S197-202.

  10. Ayyar VS. History of growth hormone therapy. Indian J Endocrinol Metab. 2011;15(Suppl 3):S162-S165.

  11. Genetic Engineering Tech (Internet). San Francisco, Ca. EE. UU: FDA Approves Genentech’s Drug to Treat Children’s Growth Disorder. (Citado 4 abril 2015). Disponible en: http://www.gene.com/media/ press-releases/4235/1985-10-18fda-approves-genentechs- drug-to-treat-ch.

  12. Cohen LE. Discovery of growth hormone and synthesis of recombinant human growth hormone, en: Cohen LE (Editor): Growth Hormone Deficiency: Physiology and Clinical Management. Springer International Publishing Switzerland. 2016; páginas 1-7.

  13. Calzada-León R, Robles VC, Altamirano BN. Uso de hormona de crecimiento humana biosintética en niños con deficiencia de hormona de crecimiento. Bol Med Hosp Infant Mex. 1993;50:102-109.

  14. Calzada-León R, Robles VC, Altamirano BN. Hormona de crecimiento biosintética extraída de células de mamífero en el manejo de niños con deficiencia de hormona de crecimiento. Bol Med Hosp Infant Mex. 1993;50:177-184.

  15. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-209.

  16. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-2481.

  17. Calzada-León R, Dorantes AL, Barrientos M. Recomendaciones de la Sociedad Mexicana de Endocrinología Pediátrica, A.C., para el uso de hormona de crecimiento en niños y adolescentes. Bol Med Hosp Infant Mex. 2005;62:362-374.

  18. Loche S, Carta L, Ibba A, Guzzetti C. Growth hormone treatment in non-growth hormone-deficient children. Ann Pediatr Endocrinol Metab. 2014;19:1-7.

  19. Pfäffle R. Hormone replacement therapy in children: The use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab. 2015;29:339-352.

  20. National Institute for Health and Clinical Excellence: Human growth hormone (Somatotropin) for the treatment of growth failure in children. NICE technology appraisal guidance. 2010;12(5).

  21. Fideleff HL, Boquete HR, Suárez MG, Azaretzky M. Burden of growth hormone deficiency and excess in children. Prog Mol Biol Transl Sci. 2016;138:143-66.

  22. Tanner JM, Whitehouse RH, Hughes PC. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children with growth hormone deficiency, low birth weight, inherited smallness, Turner’s syndrome and other complaints. Arch Dis Childhood. 1971;46:745-782.

  23. Milner RD, Russell-Fraser T, Brook CD. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol. 1979;11:15-38.

  24. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab. 1999;84:1174-1183.

  25. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Horm Res 2001;55(Suppl 2):44-48.

  26. Calzada-León R. Generalidades del uso de hormona de crecimiento. En Calzada-León R: Identificación y manejo del niño con talla baja. México: Intersistemas. 2007; páginas 1276-1828.

  27. Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: Guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95:1229-1237.

  28. Lui JC, Nilsson D, Baron J. Growth plate senescence and catch-up growth. Endoc Dev. 2011;21:23-29.

  29. Hughes IP, Harris M, Choong CS. Growth hormone treatment regimens in Australia: analysis of the first three years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Clin Endocrinol. 2012;77:62-71.

  30. García RJ, Martinez-Aguayo A, Mericq V. How to optimally manage growth hormone therapy: Survey of chilean pediatric endocrinologists. Horm Res Paediatr. 2012;77:94-99.

  31. Straetermans S, de Schepper J, Thomas M, Verlinde F, Rooman R. Validation of prediction models for near adult height in children with idiopathic growth hormone deficiency treated with growth hormone: A Belgian registry study. Horm Res. 2016;86:161-168.

  32. Grumbach MM, Bin-Abbas BS, Kaplan SL. The growth hormone cascade: progress and longterm results of growth hormone treatment in growth hormone deficiency. Horm Res. 1998;49(Suppl 2):41-57.

  33. Calzada-León R. Deficiencia de hormona de crecimiento en menores de dos años. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:761-766.

  34. Calzada-León R. Deficiencia de hormona de crecimiento en niños y adolescentes. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:767-788.

  35. Calzada-León R. Deficiencia genética de hormona de crecimiento. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007:789-810.

  36. Calzada-León R. Defectos de la línea media. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007;811-819.

  37. Calzada-León R. Daño hipofisiario inducido por radiación. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007;820-829.

  38. Mullis PE. Genetics of isolated growth hormone deficiency. J Clin Res Pediatr Endocrinol. 2010;2:52-62.

  39. Webb EA, Dattani MT. Septo-optic dysplasia. Eur J Hum Genet. 2010;18:393-397.

  40. Atapattu N, Ainsworth J, Willshaw H, Parulekar M, MacPherson L, Miller C et al. Septo-optic dysplasia: antenatal risk factors and clinical features in a regional study. Horm Res Paediatr. 2012;78:81-87.

  41. Tsubahara M, Hayashi Y, Niijima S, Yamamoto M, Kamijo T, Murata Y et al. Isolated growth hormone deficiency in two siblings because of paternal mosaicism for a mutation in the GH1 gene. Clin Endocrinol. 2012;76:420-424.

  42. Solomon BD, Bear KA, Wyllie A, Keaton AA, Dubourg C, David V et al. Genotypic and phenotypic analysis of 396 individuals with mutations in Sonic Hedgehog. J Med Genet. 2012;49:473-479.

  43. Di Iorgi N, Allegri AE, Napoli F, Bertelli E, Olivieri I, Rossi A, Maghnie M. The use of neuroimaging for assessing disorders of pituitary development. Clin Endocrinol. 2012;76:161-176.

  44. McCabe MJ, Gaston-Massuet C, Gregory LC, Alatzoglou KS, Tziaferi V, Sbai O et al. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab. 2013;98:E547-E557.

  45. Tajima T, Ishizu K, Nakamura A. Molecular and clinical findings in patients with LHX4 and OTX2 mutations. Clin Pediatr Endocrinol. 2013;22:15-23.

  46. Kempers MJ, Van der Crabben SN, de Vroede M, Alfen-Van der Velden J, Netea-Maier RT, Duim RA et al. Splice site mutations in GH1 detected in previously (genetically) undiagnosed families with congenital isolated growth hormone deficiency type II. Horm Res Paediatr. 2013;80:390-396.

  47. Desai MP, Mithbawkar SM, Upadhye PS, Rao SC, Bhatia V, Vijaykumar M. Molecular genetic studies in isolated growth hormone deficiency (IGHD). Indian J Pediatr. 2013;80:623-630.

  48. Berio A, Piazzi A. Multiple endocrinopathies (growth hormone deficiency, autoimmune hypothyroidism and diabetes mellitus) in Kearns-Sayre syndrome. Pediatr Med Chir 2013;35:137–140

  49. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev. 2014;35:376-432.

  50. Demirbilek H, Tahir S, Baran RT, Sherif M, Shah P, Ozbek MN et al. Familiar isolated growth hormone deficiency due to a novel homozygous missense mutation in the growth hormone releasing hormone receptor gene: Clinical presentation with hypoglycemia. J Clin Endocrinol Metab. 2014;99:E2730-E2734.

  51. Guo MH, Shen Y, Walvoord EC, Miller TC, Moon JE, Hirschhorn JN et al. Whole exome sequencing to identify genetic causes of short stature. Horm Res Paediatr. 2014;82:44-52.

  52. Babu D, Mellone S, Fusco I, Petri A, Walker GE, Bellone S et al. Novel mutations in the GH gene (GH1) uncover putative splicing regulatory elements. Endocrinology. 2014;155:1786-1792.

  53. Barnes N, Chemaitilly W. Endocrinopathies in survivors of childhood neoplasia. Front Pediatr. 2014;2:101-108.

  54. Personnier C, Crosnier H, Meyer P, Chevignard M, Flechtner I, Boddaert N et al. Prevalence of pituitary dysfunction after severe traumatic brain injury in children and adolescents: A large prospective study. J Clin Endocrinol Metab. 2014;99:2052-2060.

  55. Klose M, Stochholm K, Janukonyte J, Lehman Christensen L, Frystyk J, Andersen M et al. Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: Results from The Danish National Study on Posttraumatic Hypopituitarism. J Clin Endocrinol Metab. 2014;99:101-110.

  56. Salomon-Estebanez MA, Grau G, Vela A, Rodriguez A, Morteruel E, Castaño L et al. Is routine endocrine evaluation necessary after paediatric traumatic brain injury? J Endocrinol Invest. 2014;37:143-148.

  57. Macchiaroli A, Kelberman D, Auriemma RS, Drury S, Islam L, Giangiobbe S et al. A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene. 2014;534:282-285.

  58. Fritez N, Sobrier ML, Iraqi H, Vie-Luton MP, Netchine I, El Annas A et al. Molecular screening of a large cohort of moroccan patients with congenital hypopituitarism. Clin Endocrinol. 2015;82:876-884.

  59. Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: A report from the St Jude Lifetime Cohort Study. J Clin Oncol. 2015;33:492-500.

  60. Marina D, Klose M, Nordenbo A, Liebach A, Feldt- Rasmussen U. Early endocrine alterationsreflect prolonged stress and relate to one year functional outcome in patients with severe braininjury. Eur J Endocrinol. 2015;172:813-822.

  61. Demurger F, Ichkou A, Mougou-Zerelli S, Le Merrer M, Goudefroye G, Delezoide AL et al. New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015;23:92-102.

  62. Calzada-León R. Deficiencia de Hormona de Crecimiento: Características clínicas y auxológicas. En: Calzada-León R. El Sistema de la Hormona de Crecimiento. México: Ed Bermúdez; 1995:105-113.

  63. Calzada-León R. Deficiencia de hormona de crecimiento en niños. En: Sociedad Mexicana de Nutrición y Endocrinología, A.C (Calzada-León R y Escalante HA Editores). Enfermedades endócrinas en niños y adultos: Rutas diagnósticas y evaluación de riesgos. México: Intersistemas; 2001:111-117.

  64. Birzniece V, Khaw CH, Nelson AE, Meinhardt U, Ho KK. A critical evaluation of bioimpedance-spectroscopy analysis in estimating body composition during GH treatment: Comparison with bromide dilution and dual X-ray absorptiometry. Eur J Endocrinol. 2015;172:21-28.

  65. Ranke MB, Lindberg A, KIGS International Board. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Horm Res. 1997;48:62-71.

  66. Ranke MB, Lindberg A, KIGS International Board. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: An analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res. 1998;49(2):91-97.

  67. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Final height in idiopathic growth hormone deficiency: The KIGS experience. Acta Paediatr. 1999;88(Suppl 428):72-75.

  68. Bajpai A, Menon PS. Growth hormone therapy. Indian J Pediatr. 2005;72:139-144.

  69. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab. 2006;91:2047-2054.

  70. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168(5):745-753.

  71. Baronio F, Mazzanti L, Girtier Y, Tamburrino F, Fazzi A, Lupi F et al. The influence of growth hormone treatment on glucose homeostasis in growth hormone deficient children. Horm Res Paediatr. 2016;86:196-200.

  72. Lanes R, Boguszewski CL, Calzada R, Cassorla F, Fideleff H, Boquete H. Growth hormone deficiency: Transition from adolescence to adulthood. Highlights from a Latin-American Serono Symposia International Foundation Conference. J Pediatric Endocrinol Metab. 2010;23:225-233.

  73. Calzada-León R. Síndrome de Turner. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:405-420.

  74. Bondy CA. Turner Syndrome Study Group. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92:10-25.

  75. Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1487-1495.

  76. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16:54-63.

  77. Soucek O, Zapletalova J, Zemkova D, Snajderova M, Novotna D, Hirschfeldova K. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013;98:E1241-E1247.

  78. Altamirano BN, Robles VC, Calzada-León R. Bone mineral density and metabolism in Mexican girls with Turner’s syndrome under estrogens and biosynthetic human growth hormone: One year follow-up. Horm Res. 1997;48(Suppl 2):177.

  79. Ranke MB, Lindberg A, KIGS International Board. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr .1999;88(Suppl 433):122-125.

  80. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: Development and validation of mathematical models. J Clin Endocrinol Metab. 2000;85:4212-4218.

  81. Stephure DK. Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360-3366.

  82. Baxter L, Bryant J, Cave CB, Milne R. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. 2007;(1):CD003887.

  83. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92:3406-3416.

  84. Calzada-León R. Tratamiento hormonal en niñas con síndrome de Turner. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:421-425.

  85. Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Kerdanet M. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol. 2011;164:891-897.

  86. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ. Growth hormone plus childhood lowdose estrogen in Turner’s syndrome. N Engl J Med. 2011;364:1230-1242.

  87. Yavaş Abalı Z, Darendeliler F, Neyzi O. A critical appraisal of growth hormone therapy in growth hormone deficiency and Turner syndrome patients in Turkey. J Clin Res Pediatr Endocrinol. 2016;8(4):490-495.

  88. Menke LA, Sas TC, Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1151-1160.

  89. Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: Randomized, double blind, placebo controlled trial. BMJ. 2011;342:d1980.

  90. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: Results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033-2041.

  91. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119-1125.

  92. Teran E, Chesner J, Rapaport R. Growth and growth hormone: An overview. Growth Horm IGF Res. 2016;28:3-5.

  93. Calzada-León R. Nefropatías e insuficiencia renal crónica. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007 páginas:1170-1181.

  94. Mehls O, Wuhl E, Tonshoff B, Schaefer F, Nissel R, Haffner D. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr. 2008;97:1159-1164.

  95. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. German Study Group for Growth Hormone Treatment in chronic renal failure. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med. 2000;343:923-930.

  96. Nissel R, Lindberg A, Mehls O, Haffner D. Pfizer International Growth Database (KIGS) International Board. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93:1359-1365.

  97. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2012;2:CD003264.

  98. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93:1359-65.

  99. Mehls O, Lindberg A, Nissel R, Haffner D, Hokken- Koelega A, Ranke MB. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab. 2010;95:686-692.

  100. Butler MG. Prader-Willi syndrome: Obesity due to genomic imprinting. Curr Genomics. 2011;12:204-215.

  101. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader- Willi syndrome. Genet Med. 2012;14:10-26.

  102. Calzada-León R. Síndrome de Prader-Willi. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:426-444.

  103. Bieth E, Eddiry S, Gaston V, Lorenzini F, Buffet A, Conte Auriol F. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi syndrome. Eur J Hum Genet. 2015;23:252-255.

  104. Cappa M, Grossi A, Borrelli P, Ghigo E, Bellone J, Benedetti S. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome. Horm Res. 1993;39:51-55.

  105. Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr. 1998;157:890-893.

  106. Corrias A, Bellone J, Beccaria L, Bosio L, Trifiro G, Livieri C. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. J Endocrinol Invest. 2000;23:84-89.

  107. Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H et al. Endocrine disorders in children with Prader-Willi syndrome: Data from 142 children of the French database. Horm Res Paediatr 2010;74:121–128

  108. Grugni G, Crino A, Pagani S, Meazza C, Buzi F, De Toni T. Growth hormone secretory pattern in nonobese children and adolescents with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2011;24:477-481.

  109. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999;134:215-221.

  110. Tauber M, Barbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: Effect of GH therapy in 14 children. Horm Res. 2000;53:279-287.

  111. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744-749.

  112. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol. 2006;65:178-185.

  113. Ranke MB, Lindberg A, KIGS International Board. GH treatment completely normalizes adult height and improves body composition in the Prader- Willi syndrome: experience from KIGS. Horm Res. 2007;70:182-187.

  114. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol. 2008;68:919-925.

  115. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97:2307-2314.

  116. Bakker NE, Kuppens RJ, Siemensma EP, Tummersde Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC. Eight years of growth hormone treatment in children with Prader-Willi syndrome: Maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013-4022.

  117. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072-E1087.

  118. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468.

  119. Calzada-León R. Síndrome de Noonan. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:398-404.

  120. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746-759.

  121. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381:333-342.

  122. Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab. 2005;90:5377-5381.

  123. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S. Noonan syndrome: Relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91:300-306.

  124. Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non receptor-type 11. Eur J Endocrinol. 2008;159:203-208.

  125. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database”. J Pediatr Endocrinol Metab. 2008;21:267-73.

  126. Dahlgren J. GH therapy in Noonan syndrome: Review of final height data. Horm Res. 2009;72(Suppl 2):46-48.

  127. Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J Clin Endocrinol Metab. 2009;94:2338-2344.

  128. Chacko EM, Rapaport R. Short stature and its treatment in Turner and Noonan syndromes. Curr Opin Endocrinol Diabetes Obes. 2012;19:40-46.

  129. Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, Christesen HT. Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growthhormone therapy: longitudinal analysis of growthhormone- naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program. Int J Pediatr Endocrinol. 2015;2015(1):17.

  130. Munns CJ, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89:4130-4135.

  131. Calzada-León R. Deficiencia de SHOX. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:865-874.

  132. Binder G. Short stature due to SHOX deficiency: Genotype, phenotype, and therapy. Horm Res Paediatr. 2011;75:81-89.

  133. Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab. 2012;97:E1257-E1265.

  134. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL. Growth hormone is effective in treatment of short stature associated with short stature homeobox- containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92:219-228.

  135. Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G. GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial. J Clin Endocrinol Metab. 2013;98:E1383-E1392.

  136. Calzada-León R. Consecuencias y riesgos del retraso de crecimiento intrauterino. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:348-363.

  137. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev. 2007;28:219-251.

  138. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-810.

  139. Calzada-León R. Retraso de crecimiento intrauterino por alteraciones en la síntesis de hormona de crecimiento. En: Calzada-León R. Retraso de Crecimiento Intrauterino. México: Litografía Bermúdez S.A. de C.V.; 1998:171-203.

  140. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Growth hormone treatment of short children born small for gestational age or with Silver- Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report in final height. Acta Paediatr. 1996;417(Suppl):18-26.

  141. Calzada-León R. Uso de hormona de crecimiento en niños con retraso de crecimiento intrauterino. En: Calzada-León R. Retraso de Crecimiento Intrauterino. México: Litografía Bermúdez S.A. de C.V.; 1998:279-294.

  142. Albertsson-Wikland K, Boguszeski M, Karlberg J. Children born small for gestational age: Postnatal growth and hormonal status. Horm Res. 1998;49(Suppl 2):7-13.

  143. Lee PA, Chernausek SD, Hokken-Koelega ACS, Czernichow P. International small for gestational age advisory board consensus development conference statement: Management of short children born small for gestational age. Pediatrics. 2003;111:1253-1261.

  144. Calzada-León R. Tratamiento hormonal en niños con retraso de crecimiento intrauterino. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:364-373.

  145. Clayton P. Consensus Statement: Management of the child born small for gestational age through to adulthood. A consensus statement of the International Societies of Pediatric Endocrinology and the growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-810.

  146. Jung H. Growth hormone treatment for short stature in children born small for gestational age. Adv Ther. 2008;25:951-978.

  147. Chatelain P. Children born small for gestational age or with very low birth weight: clinical similarities and potential benefits of growth hormone therapy. Pediatr Endocrinol Rev. 2009;6(Suppl 4):514-518.

  148. Maiorana A. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. 2009;124:e519-e531.

  149. Bannink K. Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. J Med Econ. 2010;13:221-227.

  150. Ranke MB, Lindberg A, KIGS International Board. Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcome of short children born small for gestational age and Silver Russell syndrome treated with growth hormone: analysis of data from KIGS. Horm Res Pediatr. 2010;74:259-266.

  151. Ranke MB, Lindberg A, KIGS International Board. Prediction models for short children born small for gestational age covering the total growth phase. Analysis based on data from KIGS. BMC Med Inform Decis Mak. 2011;11:38-45.

  152. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Observed and predicted total pubertal growth during treatment with GH in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, borne small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Pediatr. 2011;75:423-432.

  153. Boguszewski M, Mericq V, Bergada I, Damiani D, Belgorosky A, Gunczler P et al. Latin American Consensus: Children born small for gestational age. BMC Pediatrics. 2011;11:66-75.

  154. Calzada-León R. Growth hormone treatment of short children born small for gestational age. Topics Endocrinol Metab. 1998;9:233-237.

  155. Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clin Endocrinol. 2007;67:485-492.

  156. Schweizer R, Martin DD, Schonau E, Ranke MB. Muscle function improves during growth hormone therapy in short children born small for gestational age: Results of a peripheral quantitative computed tomography study on body composition. J Clin Endocrinol Metab. 2008;93:2978-2983.

  157. Lem AJ, van der Kaay DC, de Ridder MA, Bakkervan Waarde WM, van der Hulst FJ, Mulder JC. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: Results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97:4096-4105.

  158. Calzada-León R. Talla baja idiopática. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:1246-1248.

  159. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210-4217.

  160. Hindmarsh PC, Brook CG. Effect of growth hormone on short normal children. Br Med J. 1987;295:573-577.

  161. Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. J Pediatr. 1993;123:215-222.

  162. McCaughey ES, Mulligan J, Voss LD, Betts PR. Randomised trial of growth hormone in short normal girls. Lancet. 1998;351:940-944.

  163. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3140-3148.

  164. Loche S, Casini MR, Ubertini GM, Cappa M. Growth hormone treatment in non-growth hormone-deficient short children. J Endocrinol Invest. 2005;28:193-198.

  165. Ranke BM, Lindberg A, Calzada-León R, KIGS International Board. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: Analysis of data from KIGS. Horm Res. 2005;63:40-47.

  166. Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5247-5253.

  167. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res. 2007;68:53-62.

  168. Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenas L, Ivarsson SA, Jonsson B. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93:4342-4350.

  169. Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ. 2011;342:c7157.

  170. Ranke MB. Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol. 2013;9:325-334.

  171. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18:901-903.

  172. Rimoin DL, Merimee TJ, McKusick VA. Sexual ateliotic dwarfism: A recessively inherited isolated deficiency of growth hormone. Trans Assoc Am Phys. 1966;79:297-311.

  173. McKusick VA, Rimoin DL. General Tom Thumb and other midgets. Sci Am. 1967;217:102-106.

  174. Frasier SD. The not-so-good old days: Working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr. 1997;131:S1-S4.

  175. Cronin MJ. Pioneering recombinant growth hormone manufacturing: Pounds produced per mile of height. J Pediatr. 1997;131:S5-S7.

  176. Lindholm J. Growth hormone: historical notes. Pituitary. 2006;9:5-10.

  177. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160:263-269.

  178. Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev. 2010;18:92-108.

  179. Gupta V. Adult growth hormone deficiency. Indian J Endocrinol Metab. 2011;15(Suppl 3):S197-202.

  180. Ayyar VS. History of growth hormone therapy. Indian J Endocrinol Metab. 2011;15(Suppl 3):S162-S165.

  181. Genetic Engineering Tech (Internet). San Francisco, Ca. EE. UU: FDA Approves Genentech’s Drug to Treat Children’s Growth Disorder. (Citado 4 abril 2015). Disponible en: http://www.gene.com/media/ press-releases/4235/1985-10-18fda-approves-genentechs- drug-to-treat-ch.

  182. Cohen LE. Discovery of growth hormone and synthesis of recombinant human growth hormone, en: Cohen LE (Editor): Growth Hormone Deficiency: Physiology and Clinical Management. Springer International Publishing Switzerland. 2016; páginas 1-7.

  183. Calzada-León R, Robles VC, Altamirano BN. Uso de hormona de crecimiento humana biosintética en niños con deficiencia de hormona de crecimiento. Bol Med Hosp Infant Mex. 1993;50:102-109.

  184. Calzada-León R, Robles VC, Altamirano BN. Hormona de crecimiento biosintética extraída de células de mamífero en el manejo de niños con deficiencia de hormona de crecimiento. Bol Med Hosp Infant Mex. 1993;50:177-184.

  185. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-209.

  186. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-2481.

  187. Calzada-León R, Dorantes AL, Barrientos M. Recomendaciones de la Sociedad Mexicana de Endocrinología Pediátrica, A.C., para el uso de hormona de crecimiento en niños y adolescentes. Bol Med Hosp Infant Mex. 2005;62:362-374.

  188. Loche S, Carta L, Ibba A, Guzzetti C. Growth hormone treatment in non-growth hormone-deficient children. Ann Pediatr Endocrinol Metab. 2014;19:1-7.

  189. Pfäffle R. Hormone replacement therapy in children: The use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab. 2015;29:339-352.

  190. National Institute for Health and Clinical Excellence: Human growth hormone (Somatotropin) for the treatment of growth failure in children. NICE technology appraisal guidance. 2010;12(5).

  191. Fideleff HL, Boquete HR, Suárez MG, Azaretzky M. Burden of growth hormone deficiency and excess in children. Prog Mol Biol Transl Sci. 2016;138:143-66.

  192. Tanner JM, Whitehouse RH, Hughes PC. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children with growth hormone deficiency, low birth weight, inherited smallness, Turner’s syndrome and other complaints. Arch Dis Childhood. 1971;46:745-782.

  193. Milner RD, Russell-Fraser T, Brook CD. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol. 1979;11:15-38.

  194. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab. 1999;84:1174-1183.

  195. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Horm Res 2001;55(Suppl 2):44-48.

  196. Calzada-León R. Generalidades del uso de hormona de crecimiento. En Calzada-León R: Identificación y manejo del niño con talla baja. México: Intersistemas. 2007; páginas 1276-1828.

  197. Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: Guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95:1229-1237.

  198. Lui JC, Nilsson D, Baron J. Growth plate senescence and catch-up growth. Endoc Dev. 2011;21:23-29.

  199. Hughes IP, Harris M, Choong CS. Growth hormone treatment regimens in Australia: analysis of the first three years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Clin Endocrinol. 2012;77:62-71.

  200. García RJ, Martinez-Aguayo A, Mericq V. How to optimally manage growth hormone therapy: Survey of chilean pediatric endocrinologists. Horm Res Paediatr. 2012;77:94-99.

  201. Straetermans S, de Schepper J, Thomas M, Verlinde F, Rooman R. Validation of prediction models for near adult height in children with idiopathic growth hormone deficiency treated with growth hormone: A Belgian registry study. Horm Res. 2016;86:161-168.

  202. Grumbach MM, Bin-Abbas BS, Kaplan SL. The growth hormone cascade: progress and longterm results of growth hormone treatment in growth hormone deficiency. Horm Res. 1998;49(Suppl 2):41-57.

  203. Calzada-León R. Deficiencia de hormona de crecimiento en menores de dos años. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:761-766.

  204. Calzada-León R. Deficiencia de hormona de crecimiento en niños y adolescentes. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:767-788.

  205. Calzada-León R. Deficiencia genética de hormona de crecimiento. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007:789-810.

  206. Calzada-León R. Defectos de la línea media. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007;811-819.

  207. Calzada-León R. Daño hipofisiario inducido por radiación. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas. 2007;820-829.

  208. Mullis PE. Genetics of isolated growth hormone deficiency. J Clin Res Pediatr Endocrinol. 2010;2:52-62.

  209. Webb EA, Dattani MT. Septo-optic dysplasia. Eur J Hum Genet. 2010;18:393-397.

  210. Atapattu N, Ainsworth J, Willshaw H, Parulekar M, MacPherson L, Miller C et al. Septo-optic dysplasia: antenatal risk factors and clinical features in a regional study. Horm Res Paediatr. 2012;78:81-87.

  211. Tsubahara M, Hayashi Y, Niijima S, Yamamoto M, Kamijo T, Murata Y et al. Isolated growth hormone deficiency in two siblings because of paternal mosaicism for a mutation in the GH1 gene. Clin Endocrinol. 2012;76:420-424.

  212. Solomon BD, Bear KA, Wyllie A, Keaton AA, Dubourg C, David V et al. Genotypic and phenotypic analysis of 396 individuals with mutations in Sonic Hedgehog. J Med Genet. 2012;49:473-479.

  213. Di Iorgi N, Allegri AE, Napoli F, Bertelli E, Olivieri I, Rossi A, Maghnie M. The use of neuroimaging for assessing disorders of pituitary development. Clin Endocrinol. 2012;76:161-176.

  214. McCabe MJ, Gaston-Massuet C, Gregory LC, Alatzoglou KS, Tziaferi V, Sbai O et al. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab. 2013;98:E547-E557.

  215. Tajima T, Ishizu K, Nakamura A. Molecular and clinical findings in patients with LHX4 and OTX2 mutations. Clin Pediatr Endocrinol. 2013;22:15-23.

  216. Kempers MJ, Van der Crabben SN, de Vroede M, Alfen-Van der Velden J, Netea-Maier RT, Duim RA et al. Splice site mutations in GH1 detected in previously (genetically) undiagnosed families with congenital isolated growth hormone deficiency type II. Horm Res Paediatr. 2013;80:390-396.

  217. Desai MP, Mithbawkar SM, Upadhye PS, Rao SC, Bhatia V, Vijaykumar M. Molecular genetic studies in isolated growth hormone deficiency (IGHD). Indian J Pediatr. 2013;80:623-630.

  218. Berio A, Piazzi A. Multiple endocrinopathies (growth hormone deficiency, autoimmune hypothyroidism and diabetes mellitus) in Kearns-Sayre syndrome. Pediatr Med Chir 2013;35:137–140

  219. Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev. 2014;35:376-432.

  220. Demirbilek H, Tahir S, Baran RT, Sherif M, Shah P, Ozbek MN et al. Familiar isolated growth hormone deficiency due to a novel homozygous missense mutation in the growth hormone releasing hormone receptor gene: Clinical presentation with hypoglycemia. J Clin Endocrinol Metab. 2014;99:E2730-E2734.

  221. Guo MH, Shen Y, Walvoord EC, Miller TC, Moon JE, Hirschhorn JN et al. Whole exome sequencing to identify genetic causes of short stature. Horm Res Paediatr. 2014;82:44-52.

  222. Babu D, Mellone S, Fusco I, Petri A, Walker GE, Bellone S et al. Novel mutations in the GH gene (GH1) uncover putative splicing regulatory elements. Endocrinology. 2014;155:1786-1792.

  223. Barnes N, Chemaitilly W. Endocrinopathies in survivors of childhood neoplasia. Front Pediatr. 2014;2:101-108.

  224. Personnier C, Crosnier H, Meyer P, Chevignard M, Flechtner I, Boddaert N et al. Prevalence of pituitary dysfunction after severe traumatic brain injury in children and adolescents: A large prospective study. J Clin Endocrinol Metab. 2014;99:2052-2060.

  225. Klose M, Stochholm K, Janukonyte J, Lehman Christensen L, Frystyk J, Andersen M et al. Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: Results from The Danish National Study on Posttraumatic Hypopituitarism. J Clin Endocrinol Metab. 2014;99:101-110.

  226. Salomon-Estebanez MA, Grau G, Vela A, Rodriguez A, Morteruel E, Castaño L et al. Is routine endocrine evaluation necessary after paediatric traumatic brain injury? J Endocrinol Invest. 2014;37:143-148.

  227. Macchiaroli A, Kelberman D, Auriemma RS, Drury S, Islam L, Giangiobbe S et al. A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene. 2014;534:282-285.

  228. Fritez N, Sobrier ML, Iraqi H, Vie-Luton MP, Netchine I, El Annas A et al. Molecular screening of a large cohort of moroccan patients with congenital hypopituitarism. Clin Endocrinol. 2015;82:876-884.

  229. Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: A report from the St Jude Lifetime Cohort Study. J Clin Oncol. 2015;33:492-500.

  230. Marina D, Klose M, Nordenbo A, Liebach A, Feldt- Rasmussen U. Early endocrine alterationsreflect prolonged stress and relate to one year functional outcome in patients with severe braininjury. Eur J Endocrinol. 2015;172:813-822.

  231. Demurger F, Ichkou A, Mougou-Zerelli S, Le Merrer M, Goudefroye G, Delezoide AL et al. New insights into genotype-phenotype correlation for GLI3 mutations. Eur J Hum Genet. 2015;23:92-102.

  232. Calzada-León R. Deficiencia de Hormona de Crecimiento: Características clínicas y auxológicas. En: Calzada-León R. El Sistema de la Hormona de Crecimiento. México: Ed Bermúdez; 1995:105-113.

  233. Calzada-León R. Deficiencia de hormona de crecimiento en niños. En: Sociedad Mexicana de Nutrición y Endocrinología, A.C (Calzada-León R y Escalante HA Editores). Enfermedades endócrinas en niños y adultos: Rutas diagnósticas y evaluación de riesgos. México: Intersistemas; 2001:111-117.

  234. Birzniece V, Khaw CH, Nelson AE, Meinhardt U, Ho KK. A critical evaluation of bioimpedance-spectroscopy analysis in estimating body composition during GH treatment: Comparison with bromide dilution and dual X-ray absorptiometry. Eur J Endocrinol. 2015;172:21-28.

  235. Ranke MB, Lindberg A, KIGS International Board. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Horm Res. 1997;48:62-71.

  236. Ranke MB, Lindberg A, KIGS International Board. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: An analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res. 1998;49(2):91-97.

  237. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Final height in idiopathic growth hormone deficiency: The KIGS experience. Acta Paediatr. 1999;88(Suppl 428):72-75.

  238. Bajpai A, Menon PS. Growth hormone therapy. Indian J Pediatr. 2005;72:139-144.

  239. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab. 2006;91:2047-2054.

  240. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168(5):745-753.

  241. Baronio F, Mazzanti L, Girtier Y, Tamburrino F, Fazzi A, Lupi F et al. The influence of growth hormone treatment on glucose homeostasis in growth hormone deficient children. Horm Res Paediatr. 2016;86:196-200.

  242. Lanes R, Boguszewski CL, Calzada R, Cassorla F, Fideleff H, Boquete H. Growth hormone deficiency: Transition from adolescence to adulthood. Highlights from a Latin-American Serono Symposia International Foundation Conference. J Pediatric Endocrinol Metab. 2010;23:225-233.

  243. Calzada-León R. Síndrome de Turner. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:405-420.

  244. Bondy CA. Turner Syndrome Study Group. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92:10-25.

  245. Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1487-1495.

  246. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16:54-63.

  247. Soucek O, Zapletalova J, Zemkova D, Snajderova M, Novotna D, Hirschfeldova K. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013;98:E1241-E1247.

  248. Altamirano BN, Robles VC, Calzada-León R. Bone mineral density and metabolism in Mexican girls with Turner’s syndrome under estrogens and biosynthetic human growth hormone: One year follow-up. Horm Res. 1997;48(Suppl 2):177.

  249. Ranke MB, Lindberg A, KIGS International Board. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr .1999;88(Suppl 433):122-125.

  250. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: Development and validation of mathematical models. J Clin Endocrinol Metab. 2000;85:4212-4218.

  251. Stephure DK. Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360-3366.

  252. Baxter L, Bryant J, Cave CB, Milne R. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. 2007;(1):CD003887.

  253. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92:3406-3416.

  254. Calzada-León R. Tratamiento hormonal en niñas con síndrome de Turner. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:421-425.

  255. Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Kerdanet M. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol. 2011;164:891-897.

  256. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ. Growth hormone plus childhood lowdose estrogen in Turner’s syndrome. N Engl J Med. 2011;364:1230-1242.

  257. Yavaş Abalı Z, Darendeliler F, Neyzi O. A critical appraisal of growth hormone therapy in growth hormone deficiency and Turner syndrome patients in Turkey. J Clin Res Pediatr Endocrinol. 2016;8(4):490-495.

  258. Menke LA, Sas TC, Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2010;95:1151-1160.

  259. Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: Randomized, double blind, placebo controlled trial. BMJ. 2011;342:d1980.

  260. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: Results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033-2041.

  261. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003;88:1119-1125.

  262. Teran E, Chesner J, Rapaport R. Growth and growth hormone: An overview. Growth Horm IGF Res. 2016;28:3-5.

  263. Calzada-León R. Nefropatías e insuficiencia renal crónica. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007 páginas:1170-1181.

  264. Mehls O, Wuhl E, Tonshoff B, Schaefer F, Nissel R, Haffner D. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr. 2008;97:1159-1164.

  265. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O. German Study Group for Growth Hormone Treatment in chronic renal failure. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med. 2000;343:923-930.

  266. Nissel R, Lindberg A, Mehls O, Haffner D. Pfizer International Growth Database (KIGS) International Board. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93:1359-1365.

  267. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2012;2:CD003264.

  268. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab. 2008;93:1359-65.

  269. Mehls O, Lindberg A, Nissel R, Haffner D, Hokken- Koelega A, Ranke MB. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab. 2010;95:686-692.

  270. Butler MG. Prader-Willi syndrome: Obesity due to genomic imprinting. Curr Genomics. 2011;12:204-215.

  271. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader- Willi syndrome. Genet Med. 2012;14:10-26.

  272. Calzada-León R. Síndrome de Prader-Willi. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:426-444.

  273. Bieth E, Eddiry S, Gaston V, Lorenzini F, Buffet A, Conte Auriol F. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi syndrome. Eur J Hum Genet. 2015;23:252-255.

  274. Cappa M, Grossi A, Borrelli P, Ghigo E, Bellone J, Benedetti S. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome. Horm Res. 1993;39:51-55.

  275. Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr. 1998;157:890-893.

  276. Corrias A, Bellone J, Beccaria L, Bosio L, Trifiro G, Livieri C. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. J Endocrinol Invest. 2000;23:84-89.

  277. Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H et al. Endocrine disorders in children with Prader-Willi syndrome: Data from 142 children of the French database. Horm Res Paediatr 2010;74:121–128

  278. Grugni G, Crino A, Pagani S, Meazza C, Buzi F, De Toni T. Growth hormone secretory pattern in nonobese children and adolescents with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2011;24:477-481.

  279. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999;134:215-221.

  280. Tauber M, Barbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: Effect of GH therapy in 14 children. Horm Res. 2000;53:279-287.

  281. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744-749.

  282. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol. 2006;65:178-185.

  283. Ranke MB, Lindberg A, KIGS International Board. GH treatment completely normalizes adult height and improves body composition in the Prader- Willi syndrome: experience from KIGS. Horm Res. 2007;70:182-187.

  284. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol. 2008;68:919-925.

  285. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97:2307-2314.

  286. Bakker NE, Kuppens RJ, Siemensma EP, Tummersde Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC. Eight years of growth hormone treatment in children with Prader-Willi syndrome: Maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013-4022.

  287. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072-E1087.

  288. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468.

  289. Calzada-León R. Síndrome de Noonan. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:398-404.

  290. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746-759.

  291. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381:333-342.

  292. Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab. 2005;90:5377-5381.

  293. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S. Noonan syndrome: Relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91:300-306.

  294. Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non receptor-type 11. Eur J Endocrinol. 2008;159:203-208.

  295. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database”. J Pediatr Endocrinol Metab. 2008;21:267-73.

  296. Dahlgren J. GH therapy in Noonan syndrome: Review of final height data. Horm Res. 2009;72(Suppl 2):46-48.

  297. Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J Clin Endocrinol Metab. 2009;94:2338-2344.

  298. Chacko EM, Rapaport R. Short stature and its treatment in Turner and Noonan syndromes. Curr Opin Endocrinol Diabetes Obes. 2012;19:40-46.

  299. Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, Christesen HT. Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growthhormone therapy: longitudinal analysis of growthhormone- naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program. Int J Pediatr Endocrinol. 2015;2015(1):17.

  300. Munns CJ, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89:4130-4135.

  301. Calzada-León R. Deficiencia de SHOX. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:865-874.

  302. Binder G. Short stature due to SHOX deficiency: Genotype, phenotype, and therapy. Horm Res Paediatr. 2011;75:81-89.

  303. Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab. 2012;97:E1257-E1265.

  304. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL. Growth hormone is effective in treatment of short stature associated with short stature homeobox- containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92:219-228.

  305. Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, Kalifa G. GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial. J Clin Endocrinol Metab. 2013;98:E1383-E1392.

  306. Calzada-León R. Consecuencias y riesgos del retraso de crecimiento intrauterino. En: Calzada-León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:348-363.

  307. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev. 2007;28:219-251.

  308. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-810.

  309. Calzada-León R. Retraso de crecimiento intrauterino por alteraciones en la síntesis de hormona de crecimiento. En: Calzada-León R. Retraso de Crecimiento Intrauterino. México: Litografía Bermúdez S.A. de C.V.; 1998:171-203.

  310. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Growth hormone treatment of short children born small for gestational age or with Silver- Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report in final height. Acta Paediatr. 1996;417(Suppl):18-26.

  311. Calzada-León R. Uso de hormona de crecimiento en niños con retraso de crecimiento intrauterino. En: Calzada-León R. Retraso de Crecimiento Intrauterino. México: Litografía Bermúdez S.A. de C.V.; 1998:279-294.

  312. Albertsson-Wikland K, Boguszeski M, Karlberg J. Children born small for gestational age: Postnatal growth and hormonal status. Horm Res. 1998;49(Suppl 2):7-13.

  313. Lee PA, Chernausek SD, Hokken-Koelega ACS, Czernichow P. International small for gestational age advisory board consensus development conference statement: Management of short children born small for gestational age. Pediatrics. 2003;111:1253-1261.

  314. Calzada-León R. Tratamiento hormonal en niños con retraso de crecimiento intrauterino. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:364-373.

  315. Clayton P. Consensus Statement: Management of the child born small for gestational age through to adulthood. A consensus statement of the International Societies of Pediatric Endocrinology and the growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804-810.

  316. Jung H. Growth hormone treatment for short stature in children born small for gestational age. Adv Ther. 2008;25:951-978.

  317. Chatelain P. Children born small for gestational age or with very low birth weight: clinical similarities and potential benefits of growth hormone therapy. Pediatr Endocrinol Rev. 2009;6(Suppl 4):514-518.

  318. Maiorana A. Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics. 2009;124:e519-e531.

  319. Bannink K. Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. J Med Econ. 2010;13:221-227.

  320. Ranke MB, Lindberg A, KIGS International Board. Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcome of short children born small for gestational age and Silver Russell syndrome treated with growth hormone: analysis of data from KIGS. Horm Res Pediatr. 2010;74:259-266.

  321. Ranke MB, Lindberg A, KIGS International Board. Prediction models for short children born small for gestational age covering the total growth phase. Analysis based on data from KIGS. BMC Med Inform Decis Mak. 2011;11:38-45.

  322. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Observed and predicted total pubertal growth during treatment with GH in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, borne small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Pediatr. 2011;75:423-432.

  323. Boguszewski M, Mericq V, Bergada I, Damiani D, Belgorosky A, Gunczler P et al. Latin American Consensus: Children born small for gestational age. BMC Pediatrics. 2011;11:66-75.

  324. Calzada-León R. Growth hormone treatment of short children born small for gestational age. Topics Endocrinol Metab. 1998;9:233-237.

  325. Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clin Endocrinol. 2007;67:485-492.

  326. Schweizer R, Martin DD, Schonau E, Ranke MB. Muscle function improves during growth hormone therapy in short children born small for gestational age: Results of a peripheral quantitative computed tomography study on body composition. J Clin Endocrinol Metab. 2008;93:2978-2983.

  327. Lem AJ, van der Kaay DC, de Ridder MA, Bakkervan Waarde WM, van der Hulst FJ, Mulder JC. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: Results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97:4096-4105.

  328. Calzada-León R. Talla baja idiopática. En: Calzada- León R. Identificación y manejo del niño con talla baja. México: Intersistemas; 2007:1246-1248.

  329. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210-4217.

  330. Hindmarsh PC, Brook CG. Effect of growth hormone on short normal children. Br Med J. 1987;295:573-577.

  331. Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. J Pediatr. 1993;123:215-222.

  332. McCaughey ES, Mulligan J, Voss LD, Betts PR. Randomised trial of growth hormone in short normal girls. Lancet. 1998;351:940-944.

  333. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3140-3148.

  334. Loche S, Casini MR, Ubertini GM, Cappa M. Growth hormone treatment in non-growth hormone-deficient short children. J Endocrinol Invest. 2005;28:193-198.

  335. Ranke BM, Lindberg A, Calzada-León R, KIGS International Board. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: Analysis of data from KIGS. Horm Res. 2005;63:40-47.

  336. Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5247-5253.

  337. Ranke MB, Lindberg A, Calzada-León R, KIGS International Board. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res. 2007;68:53-62.

  338. Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenas L, Ivarsson SA, Jonsson B. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93:4342-4350.

  339. Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ. 2011;342:c7157.

  340. Ranke MB. Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol. 2013;9:325-334.




2020     |     www.medigraphic.com